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Abstract
Background: An important challenge to pulmonary arterial hypertension (PAH) diagnosis and treatment is early detection
of occult pulmonary vascular pathology. Symptoms are frequently confused with other disease entities that lead to
inappropriate interventions and allow for progression to advanced states of disease. There is a significant need to develop
new markers for early disease detection and management of PAH.
Methodolgy and Findings: Exhaled breath condensate (EBC) samples were compared from 30 age-matched normal healthy
individuals and 27 New York Heart Association functional class III and IV idiopathic pulmonary arterial hypertenion (IPAH)
patients, a subgroup of PAH. Volatile organic compounds (VOC) in EBC samples were analyzed using gas chromatography/
mass spectrometry (GC/MS). Individual peaks in GC profiles were identified in both groups and correlated with pulmonary
hemodynamic and clinical endpoints in the IPAH group. Additionally, GC/MS data were analyzed using autoregression
followed by partial least squares regression (AR/PLSR) analysis to discriminate between the IPAH and control groups. After
correcting for medicaitons, there were 62 unique compounds in the control group, 32 unique compounds in the IPAH
group, and 14 in-common compounds between groups. Peak-by-peak analysis of GC profiles of IPAH group EBC samples
identified 6 compounds significantly correlated with pulmonary hemodynamic variables important in IPAH diagnosis. AR/
PLSR analysis of GC/MS data resulted in a distinct and identifiable metabolic signature for IPAH patients.
Conclusions: These findings indicate the utility of EBC VOC analysis to discriminate between severe IPAH and a healthy
population; additionally, we identified potential novel biomarkers that correlated with IPAH pulmonary hemodynamic
variables that may be important in screening for less severe forms IPAH.
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Introduction
An important challenge to pulmonary arterial hypertension
(PAH) diagnosis and treatment is the early detection of occult
pulmonary vascular pathology. Despite recognized risk factors for
the disease, patients often present clinically only after a prolonged
interval of symptoms. These symptoms are frequently confused
with other disease entities, sometimes leading to inappropriate
interventions and further progression to advanced states of disease.
Even with proper diagnosis and therapy, the ability to judge the
effectiveness of intervention is limited by the lack of assessment
tools and biological markers.
Assessment tests such as the New York Heart Association
(NYHA) Functional Classification and the 6 minute walk distance
(6MWD) and biomarkers such as brain natriuretic peptide (BNP),
though helpful, are limited in their ability to show PAH disease
progression or quiescence. There is an unmet need to develop new
markers for PAH disease detection and management that are
valid, reliable and simple to obtain. Analysis of exhaled breath has
been used to detect and monitor diverse pulmonary and systemic
diseases such as oxidant-induced airway injury [1], aspirin-induced
asthma [2], lung cancer [3,4] COPD [5], tuberculosis [6], lung
transplant rejection [7], breast cancer [8], heart transplant
rejection [9], diabetes mellitus [10], and unstable angina [11].
Investigation in our laboratory using non-invasive exhaled
breath condensate (EBC) analysis has shown that vascular
endothelial growth factor, leukotriene B4, prostaglandin E2,
isoprostane, nitrates and nitrites can be isolated from EBC in
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humans exposed to altitude [12] and ozone [1]. The purpose of
this study was to analyze the metabolic signature of volatile
organic compounds (VOC) in EBC in patients with class 3 and 4
idiopathic PAH (IPAH) using gas chromatography/mass spec-
trometry (GC/MS). We compared this metabolic signature against
age-matched healthy controls. It is hoped that this analysis is a first
step in identifying new markers that can potentially be used to
screen for less severe IPAH (classes I and II).
Methods And Materials
Ethics Statement
This study was approved by the University of California, Davis,
Office of Human Research Protection Institutional Review Board
(protocol #200917227-1). Written informed consent was obtained
from participants and the study was conducted according to
principles expressed in the Declaration of Helsinki.
Subjects
A total of 60 subjects ages 32–78 were recruited, with 30 healthy
control subjects (8 males, 22 femlaes) and initially 30 functional
class 3/4 IPAH who had undergone diagnostic right heart
catheterization. The data from 3 IPAH subjects were insufficient
for analysis reducing the final the IPAH group to 8 males and 19
females. Potential IPAH subjects were excluded if they were
classified as functional class I/II IPAH or had anorexic drug-
induced PAH, were HIV positive, were pregnant, had congenital
heart disease, were currently smoking or had collagen-vascular
disease. Control subjects were all non-smokers and pregnant
women were excluded. An attempt was made to match age and
body mass index (BMI).
Research Design and Data Collection
Subjects had their exhaled nitric oxide (ExNO) measured
followed by collection of EBC. ExNO was measured with a
chemiluminescence nitric oxide analyzer (Sievers, Boulder, CO)
using the restricted breath technique at flow rate of 50 ml/s [13].
Historical 6MWD, New York functional class, BNP, hemody-
namic measures and pulmonary function data was extracted from
IPAH patients’ medical records for correlation analysis.
EBC samples were collected as subjects sat quietly with a nose
clip on breathing into the Jaeger EcoScreen (Viasys Healthcare,
Conshohocken, PA) apparatus [12]. 0.5 mL EBC samples were
stored at 280uC in borosilicate vials and analyzed for VOC in a
single batch using solid-phase microextraction (SPME). For
SPME, EBC samples were thawed, 0.5 mL saturated NaCl
solution added and sample vials placed on a chilled tray of a
autosampler in randomized fashion. VOCs were sampled from the
headspace using carboxen/polydimethylsiloxane df 75 mm (par-
tially crosslinked [black hub]) SPME fibers (Supelco, St. Louis,
MO) [14]. For analysis, EBC samples were transferred into a
heater and agitated at 90uC with SPME tip exposed to the
headspace. After sampling, the SPME was inserted into the heated
inlet of a Varian 3800 GC with a 4000 Ion Trap MS (scanned
mass-to-charge ratio (m/z) range 35–600 Th) equipped with an
electron ionization source and a VF-5 ms 5% phenol/95% PDMS
GC column (Varian, Walnut Creek, CA). The GC oven cycle was
optimized for separation of benchmark human EBC samples.
Data Analysis
Exhaled Breath Condensate Gas Chromatograms/Mass
Spectra Analysis. In order to compare EBC GC/MS profiles
of control and IPAH subjects, whole chromatogram analysis and
specific peak comparisons were used to test for statistically
significant differences (p,0.05) between groups. Baseline correc-
tion was applied to remove the shifted regions of all chromato-
grams. A peak was defined as a minimum height of 500 ion counts.
GC column bleed peaks (siloxanes) or extraneous contaminats (e.g.
phtalates) were excluded. The height values of all peaks in the
chromatogram were summed for each individual chromatogram
(Shi) and the average was calculated (h). A correction coefficient r
was then calculated as ri =Shi/h. Each chromatogram was
corrected by dividing the peak height value by ri in order to
detect possible outliers and/or minimize the error in the sampling
step. Then, peaks were normalized based on the height of the
same peak of each sample to make the comparison on the same
scale. Peaks with unacceptably low signal-to-noise ratios were not
used. Across all of the chromatograms, 2668 peaks were identified
using this approach.
To be considered unique, chromatograms of 70% of the
subjects in a given group had to contain a given peak, while
chromatograms of subjects in the other group did not contain the
same peak. Peaks were considered in-common if chromatograms
of subjects in both groups contained a given peak. We identified 62
unique peaks from the control group, 48 unique peaks from the
IPAH group and 19 in-common peaks. In order to control for
peaks that may have been affected by medications and/or dietary
supplements being taken by the IPAH subjects, medications/
dietary supplements were tabulated (see Table S1); 112 unique
medications/dietary supplements were identified. A MANOVA
was run using each medication/dietary supplement that was taken
by 4 or more IPAH subjects as a grouping factor; if there was a
statistically significant drug effect for a given peak, peak height
data for the subjects taking that drug were removed from the
database. After this, 5 peaks no longer met our criteria for an in-
common peak and were removed from the original 19 in-common
peaks for a total of 14 in-common peaks, and 16 peaks no longer
met our criteria for a unique IPAH peaks and were removed from
the original 48 unique IPAH peaks for a total of 32 unique IPAH
peaks. MANOVA was used to determine if any of the 14
remaining in-common peaks were significantly different between
groups.
GC/MS Autoregression/Partial Least Squares
Regression Analysis. GC/MS data were converted into total
ion count versus time. Each GC profile was composed of
approximately 15,000 time points which covered 255 minutes.
Baseline correction was applied to remove humps/plateaus in
some of the chromatograms [15]. Auto-regression (AR) analysis
was then used to reduce the number of variables needed to
describe chromatograms from the original time scan number to
one hundred AR coefficients [16,17]. Auto-regression analysis has
the advantage of reducing the dimensionality of chromatography
data while reducing the effects of possible signal misalignment
within different profiles [16,17]. To visually and quantitatively
compare the chromatography data of control and IPAH subjects,
partial least square regression (PLSR) using AR coefficients was
employed. PLSR further reduced the dimensionality from one
hundred AR coefficients to two latent variables (PLSR compo-
nents). The two PLSR components were then plotted against each
other to examine separation within the data. This analysis was
performed using Matlab software (MathWorks, Inc.; Natick, MA).
This model was validated using the leave-one-out validation
process. The results of this validation was used to calculate the
sensitivity, specificity and positive and negative likelihood ratios.
Chemical Identification. Chemical identities of the 15
peaks unique to the control group with the highest ion counts
and all of the unique IPAH and in-common peaks were explored.
Where necessary, the Automated Mass Spectral Deconvolution
Analysis of Exhaled Breath in Severe PAH
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and Identification System GC/MS analysis software (National
Institute of Standards and Technology {NIST} v.2.64) was used to
remove background noise and deconvolve peaks for co-eluting
compounds. The MS spectra were compared against the NIST
2005 and Wiley 2009 MS libraries of deconvolve peaks for co-
eluting compounds using NIST Mass Spectral Search Software
v.2.0. The highest probability matches were considered and
putative chemical identity was determined empirically by exam-
ining representative MS data and m/z in the data set. If the search
produced a match with a probability greater than 80%, that match
was considered to be the unknown compound (high confidence
match). In some cases, no match was found or multiple chemical
matches with very similar mass spectral fragmentation patterns
and close match probability values (e.g., for isomers) were found.
These were considered to be low confidence matches.
Correlation Analysis. The IPAH criteria endpoints of mean
pulmonary arterial pressure (mPAP), pulmonary arterial wedge
pressure (PAWP) and pulmonary vascular resistance (PVR) were
correlated with all in-common or unique normalized peak heights
of the IPAH group using Pearson-product moment correlation in
order to identify peaks for inclusion in stepwise linear regression.
mPAP, PAWP and PVR were also correlated with BNP and
ExNO. All statistical analysis was performed using SPSS software
version 21 (IBM Corp, Armonk, NY).
Results
Subject Characteristics
Table 1 shows the characteristics of the control and IPAH
groups. The IPAH group mean values for PVR, PAWP, DLCO, CI
and 6MWD (Table 2) met or exceeded the minimal criteria for
IPAH [18]. The groups were similar in the distribution of males
and females. There was no difference in age and height between
the two groups, however, the IPAH group was significantly
heavier and had greater BMIs than the control group. Addition-
ally, the IPAH group had significantly lower exhaled nitric oxide
values.
EBC GC/MS Analysis
Figure 1A shows a representative gas chromatogram for a
control and an IPAH subject superimposed on one-another.
Unique peaks found in the IPAH subject but not in the control
subject and a peak found in the control subject but not in the
IPAH subject are shown in figures 1B and 1C, respectively.
GC/MS Autoregression/Partial Least Squares Regression
Analysis
The results of the GC/MS AR/PLSR analysis is shown in
Figure 2. This analysis of the EBC metabolic signature shows that
based on cross validation, the separation acurracy obtained by
applying PLSR to AR coefficients is 75%. Using the pertinent
information extracted from the whole spectra, the classification
results suggest a good and robust seperability. Additionally, 22 out
of 27 disease (positive) samples were confirmed as positive
(sensitivity = 81.5%) and 21 out of 30 control (negative) samples
were confirmed as negative (specificity = 70.0%). The positive
likelihood ratio was 2.76 while the negative likelihood ratio was
0.368.
Chemical Identification
Two peaks unique to the control group, 10 peaks unique to the
IPAH group and 4 peaks common to both groups were identified
chemically with high confidence (Table 3). An in-common peak at
retention time of 75.479 min. had significantly greater ion counts
(p = 0.011) in the control group compared to the IPAH group.
This peak was identified as benzene, 1-methyl-4-(1-methylethnyl)-,
a volatile organic compound produced by gut microbiota [19].
Correlation and Regression Analysis
Six of the 32 IPAH unique peaks were correlated with mPAP,
PVR or PAWP (Table 4). There were no significant correlations
between BNP or ExNO and mPAP, PVR and PAWP (Table 4).
mPAP, PVR, and PAWP were used in the step-wise linear
regression analysis and are shown in Figure 3.
Discussion
Currently, pulmonary hemodynamics along with 6MWD are
common clinical measures used for the evaluation and diagnosis of
Table 1. Subject characteristics.
Control (n = 30) PAH (n=27)
Gender (n): Male 8 8
Female 22 19
Age (yrs) 52.566.8 51.6611.0
Height (m) 1.6860.08 1.67.360.08
Weight (kg) 80.0620.7 96.2629.4*
BMI (kg/m2) 28.466.7 34.369.8*
Exhaled Nitric Oxide 32.4626.7 16.3611.8*
Values are means 6 standard deviation;
* significantly different from control p#0.05; BMI = body mass index.
doi:10.1371/journal.pone.0095331.t001
Table 2. Hemodynamic and clinical endpoints for IPAH
subjects.
Endpoints Values n
MAP (mm Hg) 91.7610.9 27
SBP (mm Hg) 123.0614.9 27
DBP (mm Hg) 76.3611.0 27
mPAP (mm Hg) 49.4611.0 26
PAPSYS (mm Hg) 74.1615.2 26
PAPDIA (mm Hg) 35.2610.3 26
PAWP (mmHg) 10.664.2 26
PVR (mmHg/L/min) 705.26295.6 26
PRA (mm Hg) 10.265.1 25
Cardiac Index (L/min/m2) 2.3260.53 26
Brain Naturetic Peptide (pg/mL) 207.16245.9 24
6 Minute Walk Distance (m) 342.66112.3 23
DLCO (ml/min/mmHg) 20.467.7 21
Values are means 6 standard deviation; MAP =mean arterial pressure;
SBP = systolic blood pressure; DBP = diastolic blood pressure; mPAP =mean
pulmonary artery pressure; PAPSYS = systolic pulmonary artery pressure;
PAPDIA = diastolic pulmonary artery pressure; PAWP= pulmonary arterial wedge
pressure; PVR = pulmonary vascular resistance; DLCO = lung cabon monoxide
diffusing capacity. Note the high pulmonary arterial pressure and pulmonary
vascular resistance characteristic of pulmonary arterial hypertension.
doi:10.1371/journal.pone.0095331.t002
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IPAH [18]. In the current study the EBC metabolic signature was
discriminatory in delineating severe IPAH subjects from age-
matched controls. This in large part was due to the 48 peaks only
present in IPAH subjects’ gas chromatograms, and 62 peaks only
present in control subjects’ gas chromatograms. In addition, AR/
PLSR analysis conserves these distinguishing features while greatly
reducing the dimensionality of the data. This metabolomic
approach provides a means to compare the complex information
Figure 1. Representative gas chromatograms from a control subject (black line) and IPAH subject (grey line) (A) showing
significantly different (p#0.05) unique peaks for the control subject (B) and IPAH subject (C). An example of a head-to-tail comparison of
an experimental mass spectrum (D) of one of the identified significantly different peaks unique for the IPAH group at a retention time of 81.436 min.
(top) with a NIST/Wiley 2009 database search hit (bottom) identifying N-ethyl-Benzeneamine as giving the best match for the experimental spectrum.
doi:10.1371/journal.pone.0095331.g001
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contained in the gas chromatograms and discriminate divergent
groups, such as control and IPAH subjects in the current study. In
total, these findings highlight the potential predictive value of
VOCs in EBC for the evaluation and diagnosis of IPAH. This is
supported by a positive likelihood ratio of 2.76 and a negative
likelihood ratio of 0.37. Alternatively, the large number of unique
compounds in both the control and IPAH groups suggests that an
index for the screening of IPAH might be generated based on the
presence or absence of a number of these compounds. However,
the development and testing of such an index and the
metabolomics approach based on AR/PLRS analysis requires
further screening of a larger population of controls and individuals
with diverse forms of pulmonary hypertension, as well as,
individuals with other forms of lung disease to insure that the
markers and chromatogram features identified are specific to
IPAH.
The gas chromatograms obtained from IPAH samples would be
expected to be affected by not only the underlying disease process
but also the numerous medications the IPAH subjects were taking
during the study. Of the 112 medications taken, 16 were taken by
4 or more of the IPAH subjects, indicating that most of the
medications would not be expected to affect a large enough
number of the 27 chromatograms studied to influence the group
metabolic signature. The overall pattern is consistent with a
metabolic signature that is unique to IPAH and is modified
depending on the medications being taken. If any of the 48 IPAH
unique peaks were a direct or indirect result of a medication or its
metabolites, one would expect the height of those peaks to be
different in subjects taking the medications compared with subjects
not taking the medications. The data show that 30 of 48 IPAH
unique peaks and 9 of 19 in-common peaks were affected by
medication use; after eliminating peaks for individuals on given
medications, 32 IPAH unique peaks and 14 in-common peaks
contained a sufficient number of data points for subsequent
correlation and regression analysis. Correlation and multiple linear
regression analysis showed significant relationships between
pulmonary hemodynamic PAH criteria and specific peaks from
our GC/MS analysis (Table 4 and Figure 3). Although unknown
at this point, it is possible that some medications affected peak
heights in IPAH subjects and may have affected metabolic
pathways important in the underlying mechanisms of IPAH.
Another factor that may have influenced our results is the
significantly greater BMI in the IPAH group. This difference in
BMI can be attributed to 4 subjects that had a mean BMI of 54.1.
Removing these 4 subjects data from the dataset did not alter the
Figure 2. Plot of the results of autoregression and partial least
squares analysis-weighted components of control subjects
(dark circles) and IPAH subjects (open squares). 22 out of 27
disease (positive) samples were confirmed as positive (sensitivity
= 81.5%) and 21 out of 30 control (negative) samples were confirmed
as negative (specificity = 70.0%). The positive likelihood ratio was 2.76
while the negative likelihood ratio was 0.368.
doi:10.1371/journal.pone.0095331.g002
Table 3. Chemicals identified with ‘‘high confidence’’ for peaks found in all groups.
Peak Retention Time (min) Present In Proposed Chemical
18.843 IPAH methyl isobutyl ketone
29.003 IPAH furan, tetrahydro-2, 2, 4, 4-tetramethyl
52.031 Control oxime-, methoxy-phenyl
55.271 In-common benzaldehyde
58.237 IPAH aniline
58.730 Contol p-menth- 3 - ene
60.262 IPAH 2-menthene or other menthene isomers
65.244 IPAH m-cymene or o-cymene
71.801 In-common ethanone, 2,2-dihydroxy-1-phenyl-
75.479 In-common benzene, 1-methyl-4-(1-methylethenyl)-
81.436 IPAH benzenamine, N-ethyl-
83.224 IPAH p-menthone
96.547 IPAH benzothiazole
124.314 In-common propanoic acid, 2-methyl-, 3-hydroxy-2, 4, 4-trimethylpentyl ester
127.194 IPAH propanoic acid, 2-methyl-, 3-hydroxyhexyl ester
157.789 IPAH 1, 6-dioxacyclododecane-7, 12-dione
All peaks were identified with ‘‘high confidence’’, i.e., these structures were more likely to be the correct match than other potential candidate compounds.
doi:10.1371/journal.pone.0095331.t003
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outcomes of the AR/PLSR, correlation and regression analyses.
This finding indicates that differences in BMI do not affect the
unique characteristics of the chromatograms and individual peaks
identified in our study groups using GC/MS.
The peak-by-peak analysis of GC/MS chromatograms provided
insights into potential new biomarkers of disease severity and
progression. Six peaks that were unique to the IPAH group
significantly correlated with pulmonary hemodynamics (Table 4).
Interestingly, many identified biomarker compounds exhibited
definite structural similarities: a number of compounds differed by
only one functional group or could be formed from one another by
common cellular chemical reactions. Overall, the identified IPAH
group specific compounds appear to be more oxidized than
specific compounds identified in the control group. For example,
several substituted arenes presented in Table 3 (benzenamine; N-
ethyl-, aniline, oxime-; methoxy-phenyl, benzaldehyde; ethanone,
2,2-dihydroxy-1-phenyl-; benzene, 1-methyl-4-(1-methylethenyl)-)
could easily be converted to each other or result from common
precursors such as phenylalanine, tryptophan or tyrosine due to
bacterial degradation. Of note, benzene, 1-methyl-4-(1-methy-
lethenyl)- is found in both the control and IPAH groups and is
significantly lower in the IPAH group. Also of particular interest is
benzothiazole (RT = 96.547 min), that is unique to the IPAH
group and is significantly correlated with mPAP and PVR
(Table 4).
Recently, Cikach et al. [20] analyzed expired breath in patients
with NYHA class I-IV PAH using selected ion flow tube-mass
spectrometry. They identified low molecular mass compounds
(ammonia, propanol and alkenes) that discriminated between their
control and PAH groups and that correlated with clinical markers
of disease. These authors carried out a quantitative assessment of
21 pre-specified VOCs that were selected based on being
previously described in association to or in the context of PAH
disease. These chemical species also needed to be suitable for
analysis using SIFT MS. The common restrictions of the SIFT MS
method are an upper limit of mass of usually 240 Th and the need
for multiple reactive ions for tentative compound identification
[21]. More importantly, the SIFT MS method does not allow for
unambiguous identification of unknown species, especially those of
higher molecular mass that can have greater number of isomers.
In Cikach et al. [20], mass scanning of ion products for H3O+,
O2+, and NO+ from 14 to 200 atomic mass units was performed.
Thus, to accommodate molecular ions such as NO+M, the
parent’s mass could not be higher than approximately 170 Th. In
the present study, the SPME sorbent (carboxen/polydimethylsi-
loxane) used for pre-concentration was optimized for molecular
weight compounds of 30–225 Da. However, many compounds
outside of this range can also be trapped. Additionally, the m/z
range of the ion trap in the current study was set at 35–1000 Th
ensuring inclusion of higher molecular weight biomarkers. By
using this untargeted approach, the current study was able to
identify several compounds not previously described and merit
further investigation (Table 3). These structurally more complex
molecules may convey more information regarding their source of
origin and are less likely to result from background contamination
[22]. Our subjects were NYHA class III and IV indicating that the
metabolic profile of expired breath is altered in advanced IPAH.
Additional studies that include NYHA functional class I and II
patients would address whether the metabolites detected in the
current study could be used in early detection of PAH.
The use of ExNO as a biomarker of IPAH has not always been
successful partially due to variability seen in ExNO. ExNO has
been reported to be decreased [23–25], normal [26], or increased
[27] in PAH patients. In the current study, ExNO was significantly
lower in IPAH patients compared to control subjects. ExNO was
not correlated with any pulmonary hemodynamic endpoints in the
current study. The present study included data on two previously
described biomarkers of IPAH severity, plasma BNP and ExNO.
Elevated plasma BNP or n-terminal proBNP has been shown to be
correlated with the severity of right ventricular dysfunction in
pulmonary hypertension [28–30]. In addition, BNP has been
Figure 3. Plots of step-wise linear regression analysis of actual
vs. predicted values for mPAP, PVR, and PAWP. There were
significant associations between mPAP and peak heights at retention
times of 90.733 and 96.547 minutes (A); PVR and peak heights at
retention times of 90.733, 96.547 and 238.247 minutes (B); PAWP and
peak heights at retention times of 67.380 and 118.995 minutes (C).
doi:10.1371/journal.pone.0095331.g003
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shown to be valuable as a prognostic indicator of IPAH [31] and is
responsive to endothelin receptor antagonist treatment [32]. In
contrast, our results show that BNP was not significantly correlated
with any hemodynamic endpoints, including right atrial pressure.
Given our restricted sampling of severe IPAH the lack of
significant correlation with mPAP or any other hemodynamic
measure should not be interpreted to mean that there is no
relationship to BNP and the IPAH disease process. If a boarder
range of diseases was present in our group or if BNP and
hemodynamic values were available in our controls, then BNP
may well have correlated with hemodynamic measures.
Our findings indicate the utility of EBC VOC analysis to
discriminate between individuals with severe IPAH and age-
matched healthy individuals and provides a means for identifying
novel biomarkers significantly correlated with IPAH pulmonary
hemodynamics. This novel metabolomics approach of analyzing
VOCs in EBC in patients with IPAH using GC/MS provides a
potential diagnostic tool for classification of disease severity and
progression and will need to be confirmed in other subgroups of
PAH that differ in severity and etiology to clarify its utility in
disease management and detection.
Supporting Information
Table S1 Concomitant medication/supplements list for IPAH
subjects. Number of subjects taking each medication in parenthe-
ses.
(DOCX)
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